Share this Job


Requisition ID:  1066

San Diego, California, US


At Lundbeck, we are tirelessly dedicated to restoring brain health so every person can be their best. Headquartered in Copenhagen with sites worldwide including in La Jolla, California, Lundbeck is the only global biopharmaceutical company focused solely on brain diseases. Our legacy in neuroscience goes back seven decades and we have a long heritage of innovation. Lundbeck has developed and commercialized some of the world’s most widely prescribed therapies for psychiatric and neurological disorders. Today, we remain uncompromisingly committed to improving the quality of life for people impacted by brain disorders. Lundbeck is unique from other biopharmaceutical companies in that we are 70 percent owned by a research-focused foundation. We have a deep and productive pipeline, and we continue to bring forward symptomatic therapies to help people live better lives, while simultaneously pursuing disease-modifying treatments.


The scientist supports preclinical stage programs in Lundbeck's portfolio.  In this role, the successful candidate will be primarily responsible for leading our metabolomics capability and integrating this technology into our drug discovery programs at all stages from target identification, validation, lead optimization to development of biomarkers. A key function of this position will be characterizing the effects of small molecule drug candidates on endogenous metabolites, including lipids. 



  • Key contributor to multi-disciplinary project teams supporting target validation of novel CNS disease targets and the development of high-quality small molecule therapeutics.
  • Responsible for leading our metabolomics platform scientifically and operationally.
  • Lab-based, focused metabolomics/lipidomics method development, sample preparation and bioanalysis, and results interpretation and reporting
  • Responsible for data analysis, preparation of reports and presentations.
  • Develop and perform biochemical and cellular assays to support our drug discovery efforts



  • Ph.D. in biochemistry, analytical chemistry, or a related life sciences field or a MS in biochemistry, analytical chemistry, or a related life sciences field with 9+ years’ experience in the pharmaceutical industry or a BS in biochemistry, analytical chemistry, or a related life sciences field with 12+ years’ experience in the pharmaceutical industry with a focus on mass spectrometry-based small molecule bioanalyses
  • Demonstrated broad knowledge of LC-MS/MS-based metabolomics
  • Extensive prior LC-MS/MS method development experience to quantify endogenous small molecule metabolites in a variety of biological matrices (tissues, cells and biofluids)
  • Prior hands-on experience with multiple sample preparation techniques (extraction, SPE, derivatization, etc.) and MS data analysis, interpretation and reporting
  • Excellent skills in experimental design, implementation, troubleshooting, and data analysis
  • Excellent collaboration, communication, and presentation skills
  • Both effective team player and strong individual contributor, flexible, and able to handle multiple tasks and deliver high quality results under tight timeline



  • Experience discovering endogenous substrates and products of enzymes is preferred
  • Hands-on experience in operation of Agilent triple quadrupole or similar mass spectrometers and related LC and software systems from Agilent is strongly desired
  • Experience developing and performing biochemical and cellular assays also desirable, especially models relevant to CNS biology


Lundbeck is proud to be an equal opportunity workplace and is an affirmative action employer. We are committed to equal employement opportunity regardless of race, color, religion, sex, sexual orientation, gender identity, age, national origin, disability, protected veteran status, and any other characteristic protected by law, rule, or regulation. Lundbeck participates in E-Verify. 

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. 

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 18.1 billion in 2018 (EUR 2.4 billion; USD 2.8 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.